EGFR ‐TKIs plus local therapy demonstrated survival benefit than EGFR‐TKIs alone in EGFR‐mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases

International Journal of Cancer,Volume 0, Issue ja, -Not available-.

Source: International Journal of Cancer - November 2, 2018 Category: Cancer & Oncology Authors: Tao Jiang, Qian Chu, Huijuan Wang, Fei Zhou, Guanghui Gao, Xiaoxia Chen, Xuefei Li, Chao Zhao, Qinghua Xu, Wei Li, Fengying Wu, Anwen Xiong, Jing Zhao, Yaping Xu, Chunxia Su, Shengxiang Ren, Caicun Zhou, Fred R. Hirsch Source Type: research